SCHEMBL3745667

SCHEMBL3745667

CCOC(=O)CC1CCC(=O)N1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.44
ABL1 P00519 1/20 0.41
RIN1 Q13671 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
POLB P06746 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
TSHR P16473 2/20 0.39
HSD17B10 Q99714 1/20 0.39
KMT2A Q03164 3/20 0.39
CYP2D6 P10635 1/20 0.38
CD274 Q9NZQ7 3/20 0.37
PDCD1LG2 Q9BQ51 2/20 0.37
LMNA P02545 1/20 0.37
IRAK4 Q9NWZ3 2/20 0.37
MGAM O43451 1/20 0.36
GAA P10253 1/20 0.36
SI P14410 1/20 0.36
MGAM2 Q2M2H8 1/20 0.36
MAPT P10636 2/20 0.36
PDCD1 Q15116 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9739310 0.89 CYP2D6 (0.45) CYP1A2ABL1RIN1TDP1POLB
SCHEMBL10372330 0.84 ALDH1A1 (0.40) CYP1A2ABL1RIN1TDP1TSHR
SCHEMBL21565345 0.83 GAA (0.41) HSD17B10CD274PDCD1LG2IRAK4GAA
SCHEMBL21565414 0.83 GAA (0.41) HSD17B10CD274PDCD1LG2IRAK4GAA
SCHEMBL21565344 0.83 GAA (0.41) HSD17B10CD274PDCD1LG2IRAK4GAA
SCHEMBL8300572 0.82 CYP1A2 (0.40) CYP1A2ABL1RIN1TDP1POLB
SCHEMBL11307625 0.81 ITGB1 (0.55) CYP1A2ABL1RIN1TDP1POLB
SCHEMBL9655871 0.80 TDP1 (0.44) CYP1A2ABL1RIN1TDP1TSHR
SCHEMBL10709560 0.77 ITGB1 (0.39) CD274LMNAIRAK4PDCD1
SCHEMBL18289454 0.76 ITGB1 (0.42) SMN1; SMN2KMT2ACD274PDCD1LG2IRAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242285-B2 N-tert-butoxycarbonyl-2-pyrrolidinones and production method thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-08-14 US disclosed
US-20100280259-A1 N-Tert-Butoxycarbonyl-2-Pyrrolidinones and Production Method Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-11-04 US disclosed
US-20090163722-A1 N-TERT-BUTOXYCARBONYL-2-PYRROLIDINONES AND PRODUCTION METHOD THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-06-25 US disclosed
CN-101415676-A N-tert-butoxycarbonyl-2-pyrrolidinone compounds and method for producing the same SUMITOMO CHEMICAL CO (JP) 2009-04-22 CN disclosed
EP-2008999-A1 N-TERT-BUTOXYCARBONYL-2-PYRROLIDINONES AND PROCESS FOR PRODUCING THE SAME Sumitomo Chemical Company, Limited (JP) 2008-12-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163722-A1 N-TERT-BUTOXYCARBONYL-2-PYRROLIDINONES AND PRODUCTION METHOD THEREOF TERT, CBR1, TELO2 CYP1A2 708/4885ABL1 1120/4885RIN1 1768/4885
US-20100280259-A1 N-Tert-Butoxycarbonyl-2-Pyrrolidinones and Production Method Thereof TERT, CBR1, TELO2 CYP1A2 708/4885ABL1 1120/4885RIN1 1768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.